SCHEMBL10326375

SCHEMBL10326375

CN1C(=O)CN[C@@H]1C(c1cccc(-c2ccccc2)c1)c1cccc(-c2ccccc2)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B2 P37059 7/20 0.47
FAAH O00519 2/20 0.38
RXRA P19793 1/20 0.38
RXRB P28702 1/20 0.38
RXRG P48443 1/20 0.38
PTGER4 P35408 2/20 0.36
PTGER2 P43116 1/20 0.36
SLC6A9 P48067 1/20 0.36
ALDH1A1 P00352 1/20 0.35
HSP90AA1 P07900 1/20 0.35
PKM P14618 1/20 0.35
HTT P42858 1/20 0.35
ATM Q13315 1/20 0.35
MGLL Q99685 1/20 0.35
SLC6A2 P23975 2/20 0.34
SLC6A4 P31645 2/20 0.34
SLC6A3 Q01959 2/20 0.34
BRD4 O60885 1/20 0.34
ATP1A1 P05023 1/20 0.34
ATP1B1 P05026 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10326714 1.00 HSD17B2 (0.47) HSD17B2FAAHRXRARXRBRXRG
SCHEMBL10326647 1.00 HSD17B2 (0.47) HSD17B2FAAHRXRARXRBRXRG
SCHEMBL10326735 0.90 HSD17B2 (0.40) HSD17B2HSP90AA1SLC6A2SLC6A4SLC6A3
SCHEMBL10326715 0.90 HSD17B2 (0.40) HSD17B2HSP90AA1SLC6A2SLC6A4SLC6A3
SCHEMBL10326716 0.90 HSD17B2 (0.40) HSD17B2HSP90AA1SLC6A2SLC6A4SLC6A3
SCHEMBL10327296 0.87 HSD17B2 (0.44) HSD17B2BRD4
SCHEMBL10326648 0.87 HSD17B2 (0.44) HSD17B2BRD4
SCHEMBL10326376 0.87 HSD17B2 (0.44) HSD17B2BRD4
SCHEMBL10326159 0.87 TACR1 (0.39) HSD17B2ALDH1A1
SCHEMBL10327102 0.87 TACR1 (0.39) HSD17B2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8217204-B2 Catalyst for asymmetric hydrogenation TAKASAGO INTERNATIONAL CORPORATION (JP) 2012-07-10 US disclosed
US-8217204-B2 Catalyst for asymmetric hydrogenation TAKASAGO INTERNATIONAL CORPORATION (JP) 2012-07-10 US disclosed
US-20100324338-A1 CATALYST FOR ASYMMETRIC HYDROGENATION TAKASAGO INTERNATIONAL CORPORATION (JP) 2010-12-23 US disclosed
US-20100324338-A1 CATALYST FOR ASYMMETRIC HYDROGENATION TAKASAGO INTERNATIONAL CORPORATION (JP) 2010-12-23 US disclosed
WO-2010140636-A1 ASYMMETRIC HYDROGENATION CATALYST 高砂香料工業株式会社 (JP) 2010-12-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100324338-A1 CATALYST FOR ASYMMETRIC HYDROGENATION H1-0, H1-5, ADH5 HSD17B2 1447/4885FAAH 450/4885RXRA 2928/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.